Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of the system for detecting the expression of mir-30c-5p in predicting the curative effect of aspirin on patients with cardiovascular diseases

An aspirin and expression technology, which is applied in the application field of a system for detecting the expression of miR-30c-5p in predicting the efficacy of aspirin on patients with cardiovascular disease, can solve the problems of insufficient predictive value and poor consistency of aspirin

Active Publication Date: 2019-03-05
PEKING UNIV FIRST HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing methods for evaluating the efficacy of aspirin mainly include: detection of platelet aggregation rate induced by arachidonic acid by optical turbidimetry, detection of TXA2 metabolite levels in serum and urine, detection of platelet aggregation rate by VerifyNow, PFA-100, thromboelastometry Figures, etc., but the consistency between different detection methods is poor, and the predictive value for the clinical efficacy of aspirin on patients with cardiovascular disease and the risk of clinical cardiovascular events is insufficient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of the system for detecting the expression of mir-30c-5p in predicting the curative effect of aspirin on patients with cardiovascular diseases
  • Application of the system for detecting the expression of mir-30c-5p in predicting the curative effect of aspirin on patients with cardiovascular diseases
  • Application of the system for detecting the expression of mir-30c-5p in predicting the curative effect of aspirin on patients with cardiovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1, be used for predicting the determination of aspirin to patients with cardiovascular and cerebrovascular diseases

[0030] 350 patients with high cardiovascular risk, the inclusion criteria are as follows: age ≥ 50 years; patients with at least one of the following cardiovascular disease risk factors: stable angina, acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) surgery, coronary artery bypass graft (CABG) surgery and ischemic cerebrovascular. These 350 patients with high cardiovascular risk were obtained after excluding some patients according to the exclusion criteria. The exclusion criteria were one of the following conditions: platelet count less than 100×10 9 / L; blood system diseases; application of GP IIb / IIIa antagonists, warfarin or non-steroidal anti-inflammatory drugs; severe liver and kidney insufficiency; contraindications to aspirin use.

[0031] The clinical data of the selected patients were collected: demographic d...

Embodiment 2

[0043] Example 2. Screening of gene markers for predicting the clinical curative effect of aspirin on patients with cardiovascular and cerebrovascular diseases

[0044] Among the 40 patients who regularly took aspirin after coronary stenting, 20 typical patients who still had cardiovascular events after regular use of 100 mg / d aspirin antiplatelet therapy after coronary stenting were selected, named as the cardiovascular event group; The matched 20 patients who regularly used 100 mg / d aspirin antiplatelet therapy after coronary stenting without cardiovascular events were selected as the control group. There were no significant statistical differences in age, sex, body mass index, smoking, hypertension, hyperlipidemia, and previous myocardial infarction between the cardiovascular event group and the control group (P>0.05); There was no statistical difference in drug treatment and other aspects (P>0.05).

[0045] Quantitative PCR analyzer 7500 system was used to quantitatively ...

Embodiment 3

[0081] Example 3. Verification of microRNA markers used to predict the clinical efficacy of aspirin on patients with cardiovascular and cerebrovascular diseases

[0082] According to the detection method of platelet aggregation rate in Example 1, 310 cases of selected patients for the verification study of fluorescent quantitative PCR after microRNA screening were divided into groups, including 74 patients in the HAPR group and 236 patients in the No-HAPR group.

[0083] Whole blood microRNA was extracted from 310 patients selected for the validation study of fluorescent quantitative PCR after microRNA screening, and the extracted whole blood microRNA was reverse-transcribed and stored at -20°C; The 10 microRNAs in 2 were amplified, and the relative expression levels of these 10 microRNAs relative to U6 in the HAPR group and the No-HAPR group were quantitatively analyzed (Table 5). Correlation of clinical efficacy.

[0084] Table 5. Relative expression of 10 microRNAs in HRP ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of a system for detecting miR-30c-5p expression quantity in prediction of a curative effect of aspirin for treating cardiovascular disease patients. In the application disclosed by the invention, an ROC curve analysis is carried out on miR-30c-5p of platelet hyper-reactivity patients by taking non-platelet hyper-reactivity patients a control, the area under curve is 0.720, the sensitivity is 54.84%, and the specificity is 82.25%. The result shows that the expression quality of miR-30c-5p in venous blood of detected objects can be used for judging the clinical curative effect of aspirin for treating the cardiovascular disease patients.

Description

technical field [0001] The invention relates to the application of a system for detecting the expression of miR-30c-5p in the field of biotechnology to predict the curative effect of aspirin on patients with cardiovascular diseases. Background technique [0002] Aspirin (ASA) is a commonly used antiplatelet drug for secondary prevention of coronary heart disease patients. A large number of randomized double-blind clinical studies have confirmed that aspirin can significantly reduce the occurrence of adverse events such as malignant arrhythmia, non-fatal myocardial infarction, and sudden cardiac death. It is one of the standard treatment drugs recommended by the guidelines of the College of Cardiology (ACC) and the American Heart Association (AHA). Aspirin's inhibition of platelet aggregation has large individual differences and unpredictability in the population, which has been confirmed by many clinical studies. Although some patients take regular doses of aspirin for a lon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12Q1/6851
CPCC12Q1/6851C12Q2531/113C12Q2563/107
Inventor 刘梅林刘滕飞张婧薇冯雪茹陈夏欢
Owner PEKING UNIV FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com